- Home
- BRLT vs LTRN Comparison
BRLT vs LTRN Comparison
Compare BRLT & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRLT | LTRN |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2M | 27.6M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BRLT | LTRN |
|---|---|---|
| Price | $1.54 | $0.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $1.59 | ★ $17.50 |
| AVG Volume (30 Days) | 45.5K | ★ 295.9K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $437,483,000.00 | N/A |
| Revenue This Year | $5.18 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $1.00 | $0.76 |
| 52 Week High | $2.90 | $4.58 |
Technical Indicators
Market Signals| Indicator | BRLT | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 68.45 | 18.63 |
| Support Level | $1.26 | N/A |
| Resistance Level | $1.64 | $1.96 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 75.00 | 1.26 |
Price Performance
Historical ComparisonAbout BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.